RENB: מחיר למכירות Enochian BioSciences

The development of AI platforms for cancer therapy involves high scientific risks and patent disputes for Renovaro Inc. (RENB). The P/S ratio visualizes the dynamics of market valuation relative to revenue, where serves as the base value of the parameter. The company's genetic potential provides stability through partnerships; however, the lack of operating leverage and high laboratory costs currently render the business unprofitable.

Evaluating the scale of Renovaro Inc. (RENB) via the P/S ratio compares market capitalization to annual sales volume. This price/sales metric measures the cost of one dollar of revenue, allowing for the determination of asset overvaluation. The price/sales trend captures market expectations regarding the commercialization of genetic developments. Intellectual capital in the field of cancer immunotherapy ensures business resilience, transforming current sales into a long-term foundation of value.